46
At the recent American Society of Hematology (ASH) conference, medical professionals highlighted the ongoing challenges in treating sickle cell disease. discussions centered around the limited treatment landscape, notably after the withdrawal of Pfizer’s Oxbryta (voxelotor) from the market.
“hematologists at ASH lamented the loss of Oxbryta for sickle cell patients” (Shutterstock). Clinicians weighed the pros and cons of various treatment options, considering both disease-modifying therapies and potentially curative approaches.
Sickle Cell Treatment Options Limited Following Drug Withdrawal
Table of Contents
Table of Contents
“hematologists at ASH lamented the loss of Oxbryta for sickle cell patients” (Shutterstock). Clinicians weighed the pros and cons of various treatment options, considering both disease-modifying therapies and potentially curative approaches.
